PRQR — ProQR Therapeutics N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612940 ·
Netherlands
Last close
$1.57
Market Cap
$165.42M
52W High
$2.15
52W Low
$1.35
ADV30
686,778
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,033,000 | — | -13,649,000 | -13,383,000 | 99,034,000 | 81,088,000 | 61,436,000 |
| Dec 2025 | 4,688,000 | — | -9,097,000 | -8,920,000 | 112,756,000 | 92,413,000 | 63,382,000 |
| Sep 2025 | 2,882,000 | — | -11,284,000 | -11,006,000 | 124,349,000 | 106,883,000 | 67,278,000 |
| Jun 2025 | 3,817,000 | — | -12,249,000 | -12,179,000 | 137,537,000 | 119,765,000 | 70,554,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,791,000
Investing CF
$-1,020,000
Financing CF
$-1,836,000
CapEx
$-1,020,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-467,506,000
Inventory
—
Receivables
$5,086,000
ST Investments
$0
EBIT TTM
$-41,236,000
Pretax Income TTM
$-42,165,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,639,000
EBITDA
$-45,361,000
Free Cash Flow
$-22,495,000
Enterprise Value
$99,010,576
Total Cash
$81,088,000
Total Debt
$15,733,000
Shares Out
105,362,551
Trailing EPS
$-0.50
Book Value
$0.55
ROE
-78.1%
ROA
-23.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,906,000 | -43,446,000 | -42,184,000 | 112,756,000 | 63,382,000 | — | -52,791,000 |
| Dec 2024 | 18,905,000 | -30,472,000 | -27,763,000 | 167,958,000 | 79,398,000 | — | -36,393,000 |
| Dec 2023 | 6,514,000 | -34,790,000 | -28,119,000 | 137,883,000 | 96,493,000 | — | 21,548,000 |
| Dec 2022 | 3,594,000 | -65,159,000 | -64,424,000 | 171,321,000 | 104,640,000 | — | -68,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.68
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.57 · call volume: 5 · put volume: 1
Expected Move to 2026-07-17:
±$1.13
(71.97%) —
implied range
$0.44 –
$2.70
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | $165.34M | $4.04 | — |
| SPRO | Spero Therapeutics, Inc. | $165.60M | $2.86 | — |
| ENLV | Enlivex Ltd. | $164.88M | $0.68 | — |
| OKUR | OnKure Therapeutics, Inc. | $166.43M | $4.12 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $167.19M | $0.88 | — |
News headlines (Yahoo Finance, 1h cache)
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
2026-05-14 12:25 · Yahoo
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
2026-05-13 12:15 · Yahoo
ProQR Announces First Quarter 2026 Operating and Financial Results
2026-05-12 11:00 · Yahoo
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
2026-05-11 12:00 · Yahoo
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
2026-05-07 14:00 · Yahoo
3 Promising Penny Stocks With Market Caps Up To $600M
2026-05-06 18:05 · Yahoo
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
2026-05-04 12:00 · Yahoo
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
2026-04-30 21:30 · Yahoo
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
2026-04-30 12:00 · Yahoo
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
2026-04-08 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.